{name}
{subtitle}
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
city
~38 mi. (Trondheim, Norway, +144 more cities)
facility
St. Olavs Hospital HF ( Site 2005)
drug
belzutifan, +3 more drugs
drug type
immunotherapy, +1 more type
Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)
city
~38 mi. (Trondheim, Norway, +137 more cities)
facility
St. Olavs Hospital HF ( Site 0852)
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)
city
~38 mi. (Trondheim, Norway, +35 more cities)
facility
St Olavs Hospital ( Site 1354)
drug
favezelimab, +1 more drug
Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)
city
~38 mi. (Trondheim, Norway, +145 more cities)
facility
St Olavs Hospital ( Site 1504)
drug
pembrolizumab, +1 more drug
drug type
immunotherapy, +2 more types